Xenetic Biosciences, Inc. (XBIO) — 10-Q Filings
All 10-Q filings from Xenetic Biosciences, Inc.. Browse 5 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (5)
-
Xenetic Biosciences' Losses Widen Amid R&D Surge; Strategic Review Underway
— Nov 12, 2025 Risk: high
Xenetic Biosciences, Inc. (XBIO) reported a net loss of $509,940 for the three months ended September 30, 2025, an increase from a net loss of $436,671 in the s -
Xenetic Biosciences' Q2 Loss Widens 39% Amid R&D Spend
— Aug 12, 2025 Risk: high
Xenetic Biosciences, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods. The company's net loss f -
Xenetic Biosciences Files Q3 2024 10-Q
— Nov 12, 2024 Risk: medium
Xenetic Biosciences, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results and provided updates on its busine -
Xenetic Biosciences Q2 2024: Revenue Up, Net Loss Widens
— Aug 13, 2024 Risk: high
Xenetic Biosciences, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $726,404 and total liabilities of $1,237,221 -
Xenetic Biosciences, Inc. Files 10-Q for Period Ending March 31, 2024
— May 9, 2024 Risk: low
Xenetic Biosciences, Inc. (XBIO) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Xenetic Biosciences, Inc. filed a 10-Q report for the period endin
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX